

Resource Summary Report

Generated by [kravitz2](#) on Aug 20, 2026

Tempus

RRID:SCR_025832

Type: Tool

Proper Citation

Tempus (RRID:SCR_025832)

Resource Information

URL:

<https://www.tempus.com/?srsltid=AfmBOooE0mE1FASi3ABHLngEKJRPI0MVlxiInUqW4nFn5OVm8>

Proper Citation: Tempus (RRID:SCR_025832)

Description: Biotechnology company that specializes in collection and analysis of molecular and clinical data to advance precision medicine.

Resource Type: commercial organization

Keywords: molecular and clinical data collection, precision medicine,

Resource Name: Tempus

Resource ID: SCR_025832

Record Creation Time: 20241002T053256+0000

Record Last Update: 20260815T183223+0000

Ratings and Alerts

No rating or validation information has been found for Tempus.

No alerts have been found for Tempus.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer research communications, 5(6), 1049.

von Itzstein MS, et al. (2025) Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 639.

Rao X, et al. (2023) Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3372.